论文部分内容阅读
目的:了解23价肺炎球菌多糖疫苗对慢性阻塞性肺病(COPD)患者的预防保护效果及因此带来的经济效益。方法:从2007年10月以来曾在我院呼吸内科就诊,有完整病历资料的COPD患者资料库中,随机筛取240人入选为研究对象,随机分成疫苗组及对照组各120人。收集基线情况及通过对两组患者两年的急性发作情况、住院情况及治疗费用的跟踪随访,并对比分析两组数据。结果:疫苗组无论在COPD急性发作次数、发作持续天数、住院次数、平均住院天数及治疗成本上均显著低于对照组。疫苗组比对照组减少总治愈成本167385.18元,接种疫苗后效益成本比达到7.08,接种疫苗后净效益达到143742.18元。结论:23价肺炎球菌多糖疫苗能有效预防COPD的发作及肺部感染的严重程度和治愈时间,并显著降低COPD所致的治疗成本。
Objective: To understand the preventive and protective effects of 23-valent pneumococcal polysaccharide vaccine against chronic obstructive pulmonary disease (COPD) and its economic benefits. Methods: A total of 240 patients randomly selected from the COPD patients database who had been in our hospital for respiratory medicine and had complete medical records since October 2007 were enrolled in the study. They were randomly divided into vaccine group and control group with 120 patients each. The baseline conditions were collected and followed up for two years of acute exacerbation, hospitalization and treatment costs in both groups, and two sets of data were compared and analyzed. Results: The vaccine group was significantly lower than the control group in both the number of acute exacerbations, the duration of seizures, the number of hospitalizations, the average days of hospitalization and the cost of treatment. Vaccine group than the control group to reduce the total cost of 167,385.18 yuan of cure, the cost-benefit ratio after vaccination reached 7.08, the net benefit after vaccination reached 143,742.18 yuan. Conclusion: The 23-valent pneumococcal polysaccharide vaccine can effectively prevent the onset of COPD and the severity and healing time of pulmonary infection, and significantly reduce the treatment cost caused by COPD.